July/August 2025 • PharmaTimes Magazine • 4-5

Contents

Features

GLP-1s – pharma’s $100bn+ opportunity to redefine obesity treatment

It’s here – but will it bring your innovations to market quicker?

Executing AI responsibly in drug safety could be a game changer

How biomarkers are shaping Parkinson’s diagnosis and trials

Getting real about artificial data in drug development

Analysis

Coming out of the dark – is it a new decade for the NHS?

Attempting to decode Parkinson’s disease with AI and the cloud

Supporting the veterinary workforce is vital to public health

How agentic AI is rewriting pharma’s commercial playbook

SmartPeople

13.
Future prescribed
Transforming community prescribing through innovation

19.
Talking the talk
Why supporting representative trial participation matters

24.
International superstars
The power and potential of study tokenisation for vaccine research and post-commercialisation

36.
New surroundings
Where you're going, and what you're doing when you arrive!